Agents for the Treatment of Diabetes Mellitus

Seminars in Dialysis

Volumn 23, Issue 5, 2010, Pages 475-479

  O'Mara, Neeta Bahal ^a  

^a Dialysis Clinics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DOSE CALCULATION; GLUCOSE BLOOD LEVEL; HUMAN; MEDICATION ERROR; RENAL REPLACEMENT THERAPY;

BLOOD GLUCOSE; DIABETES MELLITUS; DRUG DOSAGE CALCULATIONS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY FAILURE, CHRONIC; MEDICATION ERRORS; RENAL DIALYSIS;

EID: 78049418307     PISSN: 08940959     EISSN: 1525139X     Source Type: Journal    
DOI: 10.1111/j.1525-139X.2010.00776.x     Document Type: Article

References (21)

1. National Kidney Foundation: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. 2007. Available at:, accessed February 10, 2010
2. United States Renal Data System: USRDS 2007 Annual Data Report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, U.S. Department of Health and Human Services, 2007
3. Lok CE, Oliver MJ, Rothwell DM, Hux JE: The growing volume of diabetes-related dialysis: a population based study. Nephrol Dial Transplant 19:3098-3103, 2004
4. Joy MS, Cefalu WT, Hogan SL, Nachman PH: Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 39:297-307, 2002
5. Shrishrimal K, Hart P, Micota F: Managing diabetes in hemodialysis patients: observations and recommendations. Cleve Clin J Med 76:649-55, 2009
6. Morgan L, Marenah CB, Jeffcoate WJ, Morgan AG: Glycated proteins as indices of glycaemic control in diabetic patients with chronic renal failure. Diabet Med 13:514-519, 1996
7. American Diabetes Association: Standards of medical care in diabetes-2010. Diabetes Care 33(Suppl. 1):S11-S61, 2010
8. Iglesias P, Diez JJ: Insulin therapy in renal disease. Diabetes Obes Metab 10:811-23, 2008
9. Halevy D, Vemireddy M: Is a target hemoglobin A1C below 7% safe in dialysis patients? Am J Kid Dis 50:166, 2007
10. Comparison of insulins. Pharmacist's Letter/Prescriber's Letter 25(10):250107, 2009
11. Lyness W, Tyler JF, Lawrence A: Renal impairment does not affect insulin aspart pharmacokinetics in type 1 diabetes. Diabetes 50(Suppl. 2):A441-2, 2001
12. McEvoy GK (senior ed): American Hospital Formulary Service. Bethesda, MD: American Society of Health-System Pharmacists, 2010
13. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 32:193-203, 2009
14. Cavanaugh KL: Diabetes management issues for patients with chronic kidney disease. Clin Diabetes 25:90-7, 2007
15. Arnoff GR, Bennett WM, Berns JS (Eds): Drug Prescribing in Renal Failure. Dosing Guidelines for Adults and Children, 5th edn. Philadelphia, PA: American College of Physicians, 2007
16. Johnson CA. 2009 Dialysis of Drugs. Available at:, accessed January 30, 2010
17. Holmes G, Galitz L, Hu P, Lyness W: Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol 60:469-76, 2005
18. Czock D, Aisenpreis U, Rasche FM, Jehle PM: Pharmacokinetics and pharmacodynamics of lispro-insulin in hemodialysis patients with diabetes mellitus. In J Clin Pharmacol Ther 41:492-97, 2003
19. Hasslacher C, Moecks J: Do analogue insulins have nephroprotective effects? Presented at the 45th Annual Meeting of the European Association for the Study of Diabetes, Vienna, Austria, September 29 - October 2, 2009. Diabetologia 52(Suppl. 1):S417, 2009 (poster)
20. Jacobsen LV, Popescu G, Plum A: Pharmcokinetics of insulin detemir in subjects with renal or hepatic impairment. Diabetologia 45(Suppl. 1):A259, 2002
21. Pscherer S, Schreyer-Zell G, Gottsmann M: Experience with insulin glargine in patients with end-stage renal disease. Program and abstracts of the 62nd Scientific Sessions of the American Diabetes Association; June 14-18, San Francisco, California, 2002, Abstract 216